A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2016
At a glance
- Drugs TPI 287 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Acronyms TPI-287-4RT
- 07 Jun 2017 Biomarkers information updated
- 05 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
- 05 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.